Revlimid: payments to doctors
Payments that named Revlimid as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $4.5M
- Providers
- 4,220
- Transactions
- 13,280
- Average per transaction
- $339
The per-transaction average — $339 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,220 providers the average total is $1,066, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bristol Myers Squibb | $4,463,927 | 99.2% |
| E.r. Squibb & Sons, L.L.C. | $34,768 | 0.8% |